Copyright
©The Author(s) 2022.
World J Methodol. Sep 20, 2022; 12(5): 438-447
Published online Sep 20, 2022. doi: 10.5662/wjm.v12.i5.438
Published online Sep 20, 2022. doi: 10.5662/wjm.v12.i5.438
Refs | Myhre et al[23], 2020 | Notz et al[24], 2020 | Luis García de Guadiana Romualdo et al[25], 2021 | Teng et al[26], 2021 | Kanberg et al[27], 2021 | Ebihara et al[28], 2022 | Alserawan et al[29], 2021 | |
Sample size and subgroup of participants, if any | 123 confirmed cases of SARS-CoV-2 infection (non-ICU survivor = 88, ICU admission/ death = 28) | 13 cases of SARS-CoV-2 infection with ARDS | 66 confirmed cases of SARS-CoV-2 infection (non-survival = 58, survival = 6) | 111 confirmed cases of SARS-CoV-2 infection and 20 healthy controls (asymptomatic = 14, mild = 12, moderate = 34, severe = 18, and convalescent = 33) | 100 confirmed cases of SARS-CoV-2 infection (mild = 24, moderate = 28, severe = 48] and 51 healthy controls | 306 confirmed cases of SARS-CoV-2 infection | 84 confirmed cases of SARS-CoV-2 infection and 20 healthy controls | |
GDF-15 level in pg/mL | Healthy controls | 13.5 (8.0–79.0) | 703.0 (501.0–949.0) | - | 582.0 (370.0-807.0) | |||
Mild | 136.4 (44.7–321.4) | 748.0 (586.0–1087.0) | - | 2051.0 (1474.0-2925.0) | ||||
Moderate | 12400.0 | 256.2 (76.1–341.0) | 3450.0 (2337.0–4105.0) | - | ||||
Severe | - | 524.8 (405.1–831.1) | 3562.0 (2458.0–5880.0) | Increased during ICU stay | ||||
Critical | 621.0 | - | - | - | ||||
Non-ICU survivor | 2187.0 (1344.0-3620.0) | - | 2590.0 (1886.0-4811.0) | - | - | - | ||
ICU admission or death | 4225.0 (3197.0-5972.0) | - | 9448.0 (6462.0-11707.0) | - | - | - | - | |
AUC and 95% CI of GDF-15 in ROC analysis | 0.78 (0.70–0.86) P < 0.001 | Not mentioned | 0.89 (0.792–0.955) P < 0.001 | 0.89 | Not mentioned | For severity: 0.764; For prognosis: 0.740 | 0.729 (0.602-0.857) P = 0.002 | |
The optimal cut-off value of GDF-15 | 2252.0 pg/mL, to differentiate non-ICU survivors and ICU admission or death | Not mentioned | 7789.00 pg/mL, to differentiate non-ICU survivors and ICU admission or death | Not mentioned | Not mentioned | Not mentioned | 1675.0 pg/mL, to recognize deprived respiratory function (SpO2/FiO2 ≤ 400) | |
Method of GDF-15 measurement | ELISA | ELISA | Electro-chemiluminescent | ELISA | Electro-chemiluminescent | ELISA | ELISA | |
Additional findings related to GDF-15 | It was associated with viral load and hypoxemia. Better prognostic significance compared to CRP, ferritin, IL-6, and procalcitonin | It was not correlated with age and BMI | Positively correlated with CRP, ferritin, and D-dimer | GDF-15 indicates the severity and closely monitor the progression of SARS-CoV-2 | Elevated GDF-15 was significantly related to hypoxemia, viral load, and worse clinical consequences | The plasma level of GDF-15 was significantly associated with the time to wean-off mechanical ventilation | Positively correlated with CRP, D-dimer, and neutrophil count and negatively correlated with lymphocyte count |
- Citation: Parchwani D, Dholariya S, Katoch C, Singh R. Growth differentiation factor 15 as an emerging novel biomarker in SARS-CoV-2 infection. World J Methodol 2022; 12(5): 438-447
- URL: https://www.wjgnet.com/2222-0682/full/v12/i5/438.htm
- DOI: https://dx.doi.org/10.5662/wjm.v12.i5.438